CTIS2022-502299-21-00招募中1 期
STP938-101
Step Pharma0 个研究点目标入组 189 人开始时间: 2023年2月1日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 189
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A study of STX-478 alone and in combination with other anticancer drugs in participants with advanced solid tumors.Advanced solid tumors including but not limited to gynecologic CancerHead and Neck Squamous Cell CarcinomaMedDRA version: 21.1Level: LLTClassification code: 10008229Term: Cervical cancer Class: 10029104MedDRA version: 21.0Level: PTClassification code: 10041823Term: Squamous cell carcinoma Class: 100000004864MedDRA version: 20.0Level: LLTClassification code: 10027475Term: Metastatic breast cancer Class: 10029104MedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104MedDRA version: 20.0Level: PTClassification code: 10033128Term: Ovarian cancer Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10014733Term: Endometrial cancer Class: 100000004864Breast CancerCTIS2023-504807-94-00Scorpion Therapeutics Inc.220
进行中（未招募）
1 期
A phase I, multicentre, open-label, dose escalation study to determine the safety and preliminary efficacy of MBS8(1V270) administered intravenously to cancer patients with advanced solid tumoursAdvanced solid tumorsMedDRA version: 21.1Level: LLTClassification code: 10065252Term: Solid tumor Class: 10029104CTIS2024-512294-26-00MonTa Biosciences ApS103
招募中
1 期
An open-label, phase I/II study of T3P-Y058-739, a genetically-modified strain of the bacterium Yersinia enterocolitica, in patients with advanced solid tumoursCTIS2023-504199-19-00T3 Pharmaceuticals AG100
进行中（未招募）
1 期
This is clinical study to test, for the first time in people, the safety (anygood or bad effects), how long the drug can stay in the body and if it cancontrol the disease of people diagnosed with advanced cancer that has notresponded to treatment, has returned after it has been treated, or cannotbe treated by surgery, drugs, or any other known treatments.CTIS2023-509969-20-00Celgene Corp.133
进行中（未招募）
1 期
First-in-human (FIH), microdosing, non-randomized, clinical trial to investigate binding of positron emission tomography tracer [68Ga]Ga-DOTA-Cys-ATH001 targeting platelet derived growth factor receptor ß in healthy subjects as compared to patients with metabolic dysfunction-associated steatohepatitis (MASH) and Primary Sclerosing Cholangitis binding (PSC, liver) and patients with fibrostenotic Crohn’s disease (CD, gastrointestinal tract [GI])Metabolic dysfunction-associated steatotic liver disease, Crohn’s disease, Primary Sclerosing CholangitisMedDRA version: 24.1Level: LLTClassification code: 10086076Term: Fibrostenotic Crohn´s disease Class: 100000004848MedDRA version: 20.0Level: PTClassification code: 10076331Term: Steatohepatitis Class: 100000004871MedDRA version: 20.1Level: LLTClassification code: 10036732Term: Primary sclerosing cholangitis Class: 10019805CTIS2023-506555-15-00Antaros Medical AB30